Australia markets open in 2 hours 36 minutes

Guerbet SA (0ELV.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
18.88+0.46 (+2.49%)
At close: 04:19PM GMT
Full screen
Previous close18.42
Bid0.00 x N/A
Ask0.00 x N/A
Day's range18.88 - 18.88
52-week range15.32 - 23.15
Avg. volume1,755
Market cap2.356M
Beta (5Y monthly)0.73
PE ratio (TTM)0.07
EPS (TTM)2.58
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    GUERBET : Revenue at 30 September 2023.

    Revenue at 30 September 2023 Activity 9-month revenue: €573.9 million, up 2.7% at CER1 Third-quarter sales remained very strong in Asia (+15.2% at CER), were stable in EMEA (+0.6%) and showed a smaller decline in the Americas (-5.2%)Expecting double-digit activity growth in the fourth quarter of 2023 thanks to the surge in sales of EluciremTM and strong momentum in Interventional Imaging Financial targets confirmed 2023 revenue up by more than 5% like-for-like and at CERRestated EBITDA margin2 o

  • GlobeNewswire

    Guerbet: CHMP positive opinion

    The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem™ (Gadopiclenol)with the indication of use for magnetic resonance imaging with contrast enhancement in adults and children aged 2 years and over If approved by the European Commission, Elucirem™ (Gadopiclenol) will mark a step forward in innovation in MRI contrast media, thus answering to the Health authorities recommendation and concerns of patients and radiologists in Europe. An MRI exam with Elucirem™ r

  • GlobeNewswire

    Guerbet: 2023 half-year results

    Half-year results 2023 Acceleration of activity Half-year revenue: €378.6 million, up 2.8% at CER1Strong acceleration of activity in the second quarter, up 6.7% at CER Profitability in line with expectations EBITDA for the first half-year: €45.9 million, compared to €50.5 million one year earlierThe restated EBITDA margin2 amounted to 12.7% of revenue 2023 objectives confirmed Revenue: expected growth of more than 5% on a like-for-like basis and at CERExpected restated EBITDA margin2 around 11%,